Despite the evidence that IDH mutations can confer the in vivo growth ability in melanoma cell lines with BRAF mutations, the biological implications of IDH mutations in melanomas and their impacts on tumorigenesis and progression remain to be elucidated [172]. Here, IDH1 is linked to melanoma.